Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Analysts at Wedbush Reiterated their “Outperform” rating for Achaogen Inc (NDAQ:AKAO) with $28.00 Target Price per Share

Wedbush Analyst Rating Change Achaogen Inc NDAQ:AKAO

Achaogen Inc (NDAQ:AKAO) Rating Reconfirmed

They currently have a $28.00 target on Achaogen Inc (NDAQ:AKAO). Wedbush’s target would suggest a potential upside of 11.07 % from the company’s previous close. This was disclosed to clients in analysts note on 6 March.

According to data compiled by Thomson Reuters, Achaogen Inc (NDAQ:AKAO)’s stock is covered by 6 equity analysts across the Street, with 0 analysts giving it a Sell rating, 4 a Buy rating, while 2 consider it a Hold. The 12-month consensus target price for the stock is $14.17, which reflects an downside potential of 43.32% over the current price.

AKAO Stock Chart

Institutional Ownership

Ecor1 Capital Llc had the largest stake with ownership of 1.68 million shares as of Q2 2015 for 2.47% of the fund’s portfolio. Nea Management Company Llc is another notably bullish investment manager who is owning 4.72 million shares of Achaogen Inc or 1.01% of their fund’s portfolio. Moreover, Sphera Funds Management Ltd. have 1.01% of their fund’s portfolio invested in the company for 1.30 million shares. The New York-based fund Spark Investment Management Llc disclosed it had purchased a stake worth about 0.06% of the investment manager’s stock portfolio in Achaogen Inc. The Cayman Islands-based fund Cqs Cayman Lp is also positive about the stock, possessing 143,865 shares or 0.04% of their fund’s portfolio.

Achaogen Inc (NDAQ:AKAO) Profile

Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

Achaogen Inc (NDAQ:AKAO) traded down -2.11% on 6 March, hitting $25. A total of 720,148 shares of the company’s stock traded hands. This is down from average of 950,899 shares. Achaogen Inc has a 52 week low of $2.59 and a 52 week high of $26.29. The company has a market cap of $857.51M and a P/E ratio of 0.

Get the latest Achaogen Inc (NDAQ:AKAO) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Analysts at Wedbush Reiterated their “Outperform” rating for Achaogen Inc (NDAQ:AKAO) with $28.00 Target Price per Share appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Analysts at Wedbush Reiterated their “Outperform” rating for Achaogen Inc (NDAQ:AKAO) with $28.00 Target Price per Share


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription